News & Press Releases

  • 30 August 2017 - PRESS RELEASE

    Ebola: Early immune response provides insight into vaccination


    The latest outbreaks of emerging, dangerous pathogens, such as Ebola, MERS-CoV or Zika, emphasise the importance of the rapid development of effective vaccines. However, being able to predict the efficacy of new vaccines is and remains a challenge in vaccine development. DZIF scientists at the Heinrich Pette Institute and the University Medical Centre Hamburg-Eppendorf (UKE) were successful in their study in assessing early on the longer-term immune response in humans after being vaccinated with the newly developed Ebola vaccine “rVSV-ZEBOV“. more ]

  • 18 August 2017 - PRESS RELEASE

    On the way to developing a new active ingredient against chronic infections


    Chronic lung infections caused by the bacterium Pseudomonas aeruginosa require complex and, in most cases, long-term treatment with antibioticsnew medication is badly needed. Scientists at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the German Center for Infection Research (DZIF) are now improving an anti-infective active ingredient with a new mode of action. The starting point is a substance that can block the pathogenicity of the bacterium and weaken its protective biofilm. more ]

  • 10 August 2017 - PRESS RELEASE

    New approach to gastritis treatment


    Scientists from the Hannover Medical School (MHH) have elucidated how Helicobacter pylori causes gastritis. Chronic infections with the globally ubiquitous pathogen can also lead to gastric ulcers and gastric cancer. The DZIF was involved in the study. more ]

  • 18 July 2017 - PRESS RELEASE

    Promising Model for Translational Research


    The German Council of Science and Humanities has given the German Centers for Health Research (DZG) a positive assessment in recognition of the DZG’s outstanding achievements. According to the Council, the DZG are a suitable model to promote translational research in specific areas of disease. In the assessment, the advisory body for the Federal Government and the State Governments (Länder) certified that the six centers play an important role in the German science system and recommended their further development. more ]

  • 13 July 2017 - PRESS RELEASE

    Likely source for global M. chimaera infection identified by whole genome sequencing


    Scientists from a European Consortium reconstructed a global Mycobacterium chimaera outbreak by whole genome sequencing. The report has identified contaminated heater-cooler units as the likely source of Mycobacterium chimaera infection in 21 open-heart surgery patients in Switzerland, Germany, the Netherlands, and the UK, and a further 12 in the USA and Australia.
    more ]

  • 05 July 2017 - PRESS RELEASE

    Molecular "Trojan horses" render infections visible


    DZIF researchers at the Helmholtz Centre for Infection Research (HZI) develop new agents and methods for the localisation and treatment of multi-resistant bacteria. Molecular probes utilise the iron transport system of bacteria to transport antibacterial agents into the bacterial cell. more ]

  • 03 July 2017 - PRESS RELEASE

    DZIF joins with international partners to train medical staff in Africa


    New health care academy in Gabon will provide doctors and health systems workers for the country and the region.more ]

  • 20 June 2017 - PRESS RELEASE

    Maximilian Muenchhoff has been honoured with the HIV/AIDS Research Award


    Some HIV-infected – and untreated children – who do not develop AIDS, control the virus in a different way from the few infected adults who remain disease-free. Dr Maximilian Muenchhoff, DZIF scientist at LMU´s Max von Pettenkofer Institute, has been honoured for characterizing the immunological mechanisms with the HIV/AIDS Research Award of the German Society of Infectious Diseases.more ]

  • 15 June 2017 - PRESS RELEASE

    Hector Award HIV goes to HPI scientists


    Prof Marcus Altfeld and Dr Angelique Hölzemer from the Heinrich Pette Institute (HPI) have been honoured with the "Hector Award HIV 2017”. Both scientists also work at the DZIF research field HIV. more ]

  • 06 June 2017 - PRESS RELEASE

    Myrcludex B: Priority for the new hepatitis D virus entry inhibitor


    The European Medicines Agency (EMA) has granted “PRIME eligibility” to Myrcludex B, and will provide priority support for its further drug development. The hepatitis B and D virus entry inhibitor was developed by DZIF scientists at the Heidelberg University Hospital.more ]

Results 21 to 30 of total 178